Company Description
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States.
The company’s lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures.
It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device.
The company sells it products through distribution partners, independent sales agents, and direct employees.
Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Country | United States |
| Founded | 2002 |
| IPO Date | Aug 30, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 14 |
| CEO | David Jenkins |
Contact Details
Address: 1670 Highway 160 West, Suite 205 Fort Mill, South Carolina 29708 United States | |
| Phone | 973 691 2000 |
| Website | catheterprecision.com |
Stock Details
| Ticker Symbol | VTAK |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001716621 |
| ISIN Number | US74933X3026 |
| Employer ID | 38-3661826 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David A. Jenkins | Chief Executive Officer and Executive Chairman |
| Margrit Thomassen CPA | Interim Chief Financial Officer and Secretary |
| Missiaen Huck | Chief Operating Officer |
| Marie-Claude Jacques | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | 8-K | Current Report |
| Feb 3, 2025 | SCHEDULE 13D/A | Filing |
| Jan 22, 2025 | EFFECT | Notice of Effectiveness |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 16, 2025 | UPLOAD | Filing |
| Jan 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 3, 2025 | SCHEDULE 13D/A | Filing |